<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001271</url>
  </required_header>
  <id_info>
    <org_study_id>910176</org_study_id>
    <secondary_id>91-C-0176</secondary_id>
    <nct_id>NCT00001271</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma</brief_title>
  <official_title>A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr&#xD;
      infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr&#xD;
      infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of&#xD;
      response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1991</start_date>
  <completion_date>April 2001</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>B Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IgG-RFB4-SMPT-dgA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with a histologic diagnosis confirmed from a pretreatment biopsy at the Laboratory&#xD;
        of Pathology, NCI of one of the following entities: Diffuse small Lymphocytic Lymphoma;&#xD;
        Follicular, Small Cleaved cell Lymphoma; Follicular, Mixed Small Cleaved and Large Cell&#xD;
        Lymphoma; Follicular Large Cell Lymphoma; Diffuse, Intermediately Differentiated&#xD;
        Lymphocytic Lymphoma; Diffuse, Small Cleaved Cell Lymphoma; Diffuse, Mixed Small and Large&#xD;
        Cell Lymphoma; Diffuse, Large Cell Lymphoma; Large Cell Immunoblastic Lymphoma; Small&#xD;
        Noncleaved Cell Lymphoma.&#xD;
&#xD;
        Presence of CD22 antigen on at least 30 percent of tumor cells.&#xD;
&#xD;
        Presence of objectively measurable sites of disease. Bone marrow positivity and circulating&#xD;
        tumor cells in the peripheral blood will be considered evaluable but not measurable&#xD;
        disease.&#xD;
&#xD;
        No patients with purely B-cell Lymphosarcoma cell leukemia without nodal or soft tissue&#xD;
        involvement.&#xD;
&#xD;
        No patients with B-cell chronic lymphocytic leukemia, or B-cell or pre-B-cell acute&#xD;
        lymphocytic leukemia, and hairy cell leukemia.&#xD;
&#xD;
        Patients with objectively measurable disease outside a radiation port or disease which has&#xD;
        clearly progressed within a radiation port.&#xD;
&#xD;
        HIV negative.&#xD;
&#xD;
        No CNS disease.&#xD;
&#xD;
        No pulmonary parenchymal disease.&#xD;
&#xD;
        Pleural effusions or ascites may be present.&#xD;
&#xD;
        Patients with progression of disease despite at least one standard combination chemotherapy&#xD;
        regimen.&#xD;
&#xD;
        No chemotherapy for at least two weeks prior to entry.&#xD;
&#xD;
        Patients who do not desire or are not candidates for autologous or allogeneic bone marrow&#xD;
        transplantation procedures.&#xD;
&#xD;
        Life expectancy of at least 3 months&#xD;
&#xD;
        Creatinine clearance greater than 60 cc per minute.&#xD;
&#xD;
        Total bilirubin less than 1.5 mg/dl.&#xD;
&#xD;
        SGPT less than 2 times the upper limit of normal.&#xD;
&#xD;
        Albumin greater than 75 percent of the lower limit of normal.&#xD;
&#xD;
        If prior treatment with doxorubicin, the radionuclide or echocardiogram ejection fraction&#xD;
        shall be at least 35 percent.&#xD;
&#xD;
        Performance status 0-2.&#xD;
&#xD;
        Not in need of current radiation therapy to alleviate local problems.&#xD;
&#xD;
        No prior exposure to murine antibodies.&#xD;
&#xD;
        No need for current corticosteroid treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. Redesigning nature's poisons to create anti-tumor reagents. Science. 1987 Nov 20;238(4830):1098-104. doi: 10.1126/science.3317828.</citation>
    <PMID>3317828</PMID>
  </reference>
  <reference>
    <citation>Thorpe PE, Detre SI, Foxwell BM, Brown AN, Skilleter DN, Wilson G, Forrester JA, Stirpe F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur J Biochem. 1985 Feb 15;147(1):197-206. doi: 10.1111/j.1432-1033.1985.tb08737.x.</citation>
    <PMID>2982609</PMID>
  </reference>
  <reference>
    <citation>Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW, et al. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer. 1988 Nov 15;42(5):792-7. doi: 10.1002/ijc.2910420527.</citation>
    <PMID>3263328</PMID>
  </reference>
  <verification_date>June 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Antigen Modulation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Ricin A Chain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

